Results 1 to 10 of about 70,330 (230)

Network meta-analysis and cost-effectiveness analysis comparing Cetuximab-β and Cetuximab for Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer [PDF]

Frontiers in Pharmacology
BackgroundThe escalating economic burden of metastatic colorectal cancer (mCRC) in China necessitates cost-effective first-line treatments. Cetuximab-β, a newer version of Cetuximab, is approved for first-line RAS/BRAF wild-type mCRC.
Rongjun Tong, Mengyu Yang, Wanjie Zhang, Mengyuan Zhou, Linning Wang, Yun Lu, Feng Chang   +6 more
doaj   +2 more sources

Berberine: a promising strategy to combat cetuximab-resistance in colorectal cancer [PDF]

BMC Cancer
Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), is approved as a front-line treatment for metastatic colorectal cancers, but limited efficacy is obtained.
Jianmin Ye, Bingchan Sun, Fengmei Xia, Guoxin Wang, Huimin Liu, Jianghua Ding, Mingfu Tong   +6 more
doaj   +2 more sources

Rap2B-mediated reprogramming of the PI3K/AKT signaling axis drives resistance to cetuximab-targeted therapy in colorectal carcinoma [PDF]

Biological Procedures Online
Background Targeted therapy resistance represents a significant clinical challenge in cancer treatment. Rap2B, a member of the Ras superfamily of small GTPases, is frequently overexpressed in various cancers and has been implicated in promoting tumor ...
Shanshan Zhang, Ying Wei, Tingting Liu, Chenhao Sun, Xiuzhen Ge, Yang Ni, Xiaonan Tang, Mridul Roy, Tingmin Chang, Xiaohong Kang   +9 more
doaj   +2 more sources

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy

Frontiers in Oncology, 2021
The epidermal growth factor receptor (EGFR) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies, such as cetuximab, poses a challenging problem.
Hannah Zaryouh, Ines De Pauw, Hasan Baysal, Patrick Pauwels, Patrick Pauwels, Marc Peeters, Marc Peeters, Jan Baptist Vermorken, Jan Baptist Vermorken, Filip Lardon, An Wouters   +10 more
doaj   +1 more source

Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells. [PDF]

PLoS ONE, 2013
Cetuximab is a chimeric mouse-human monoclonal antibody that targets the human epidermal growth factor receptor (EGFR). However, EGFR expression determined by immunohistochemistry does not predict clinical outcomes of colorectal cancer (CRC) patients ...
Kohei Shigeta, Tetsu Hayashida, Yoshinori Hoshino, Koji Okabayashi, Takashi Endo, Yoshiyuki Ishii, Hirotoshi Hasegawa, Yuko Kitagawa   +7 more
doaj   +1 more source

Cetuximab (Erbitux) [PDF]

American Journal of Neuroradiology, 2010
Cetuximab, a recombinant chimeric monoclonal antibody, has been successfully used in the treatment of the head and neck and colorectal cancers. We present a review of its mechanism of action, indications, side effects and economic issues, accompanied by a clinical example from our institution.
W, Bou-Assaly, S, Mukherji
openaire   +2 more sources

Observational, prospective, phase 4 study in patients with first‐line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum‐based therapy: DIRECT

Cancer Reports, 2022
Background Cetuximab plus platinum‐based therapy (PBT) followed by cetuximab maintenance until progression (EXTREME) is a guideline‐recommended first‐line treatment option in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN ...
Joël Guigay, Emmanuel Chamorey, Gautier Lefebvre, Maciej Rotarski, Jean‐Philippe Wagner, Emmanuel Blot, Marc Alfonsi, Audrey Seronde, Jeltje Schulten, Frédéric Peyrade, Christophe Le Tourneau   +10 more
doaj   +1 more source

Production and evaluation of cellular effects of 153Sm-DOTA-cetuximab and 177Lu-DOTA-cetuximab radioconjugates [PDF]

مجله علوم و فنون هسته‌ای, 2023
Antibody-based radiopharmaceuticals are of increasing interest today in cancer imaging and radiotherapy. The cetuximab monoclonal antibody binds to the epidermal growth factor receptor (EGFR) and thus provides therapeutic and diagnostic protocols against
K. Yavari, M. Ghanadi Maragheh
doaj   +1 more source

AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer

BMC Cancer, 2022
Background The receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) is overexpressed and an important therapeutic target in Head and Neck cancer (HNC).
Mari Iida, Nellie K. McDaniel, Kourtney L. Kostecki, Noah B. Welke, Carlene A. Kranjac, Peng Liu, Colin Longhurst, Justine Y. Bruce, Seungpyo Hong, Ravi Salgia, Deric L. Wheeler   +10 more
doaj   +1 more source

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. [PDF]

, 2015
We hypothesized that aberrations activating epidermal growth factor receptor (EGFR) via dimerization would be more sensitive to anti-dimerization agents (e.g., cetuximab).
Bazhenova, Lyudmila, Greenberg, Jerry P, Kouznetsova, Valentina L, Kurzrock, Razelle, Stewart, David J, Tsigelny, Igor F, Wheler, Jennifer J   +6 more
core   +7 more sources